Hear from health care professionals about Tresiba® (insulin degludec)
Novo Nordisk is committed to providing information to help you understand what Tresiba® may offer your patients with diabetes. Below are videos and articles that were created to demonstrate why experts in the field have chosen to prescribe Tresiba®.
TRESIBA® SPEAKER SERIES
Industry leader James R. Gavin, III, MD, PhD, discusses the clinical pharmacology of Tresiba®.
START THE JOURNEY
Philip Woodham, MD, a diabetes specialist, discusses choosing and then starting patients on Tresiba®.
BASAL INSIGHTS
Steven Edelman, MD, and Stephen Brunton, MD, discuss key topics related to Tresiba® in this article and video series.
Tresiba® Speaker Series
with James R. Gavin, III, MD, PhD
The Tresiba® Speaker Series features industry leader Dr Gavin covering the clinical pharmacology of Tresiba®, including the mechanism of protraction and duration of action.
At the molecular level
Dr Gavin examines the mechanism of protraction of Tresiba® and how the basal insulin’s molecular makeup contributes to its long duration of action.
Duration of action
Dr Gavin discusses the pharmacokinetics behind the long duration of action of Tresiba® and what it means for patients with diabetes.
Start the Journey
Hear Dr Woodham discuss how he decides if Tresiba® is right for his patients in the Start the Journey video.
Why I prescribe Tresiba® for my patients with diabetes
Dr Woodham explains how he talks to his patients about their diabetes and why he chooses Tresiba® for his appropriate patients.
The safety outcomes data and other differentiating factors solidified Tresiba® as my go-to basal insulin for patients with type 2 diabetes. I also discuss Tresiba® with my colleagues and encourage them to prescribe Tresiba® for their appropriate patients.
PHILIP WOODHAM, MD
Endocrinologist
Hackensack, NJ
Basal Insights
In the Basal Insights article and video series, endocrinologist Dr Steven Edelman and primary care physician Dr Stephen Brunton discuss key topics related to prescribing Tresiba® for adult patients.
An endocrinologist’s point of view
Dr Edelman explores the efficacy and safety of Tresiba®.
Primary care perspective
Primary care physician Dr Brunton on the Tresiba® duration of action.
Insulin pens and primary care
Dr Brunton gives his take on prescribing Tresiba® FlexTouch®.
Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.
Important Safety Information
Contraindications
- Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients
Warnings and Precautions
- Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
- Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
- Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
- Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
- As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
- Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered
Adverse Reactions
- Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain
Drug Interactions
- There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
- Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
- Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
- Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine
Please click here for Tresiba® Prescribing Information.